Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Genprex, Inc. - Common Stock (NQ:GNPX)

7.350 -0.320 (-4.17%)
Streaming Delayed Price Updated: 1:51 PM EDT, Jul 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Genprex, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Receives Fast Track Designation for Proprietary Immunogene Therapy
Via Investor Brand Network
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
Genprex Inc. (NASDAQ: GNPX) CMO Discusses Recent Company Announcements in Bell2Bell Podcast Episode
Via Investor Brand Network
Genprex Inc. (NASDAQ: GNPX) CMO Video Discusses Advances in Company’s Fight Against Tumors
Via Investor Brand Network
Genprex Inc.’s (NASDAQ: GNPX) Inspiring Patient Video on Gene Therapy’s Potential in NSCLC Treatment
Via Investor Brand Network
BioMedNewsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Flagship Candidate Could Potentially Reshape NSCLC Landscape
Via Investor Brand Network
Genprex Inc. (NASDAQ: GNPX) Announces Positive Data From Phase 1 Clinical Trial Evaluating REQORSA(R) Immunogene Therapy for Late-Stage Non-Small Cell Lung Cancer
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Chief Medical Officer Featured Guest on Latest Bell2Bell Release
Via Investor Brand Network
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Eyes Broad-Based Application Potential of ONCOPREX(R) Nanoparticle Delivery System
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Releases Video Featuring Clinical Trial Patient Sharing Study Experience
Via Investor Brand Network
News headline image
Genprex (NASDAQ:GNPX) Releases New Patient Video Interview Describing Positive Experience In Clinical Trial
Via ACCESSWIRE
News headline image
Genprex (NASDAQ: GNPX) Releases New Patient Video Interview Describing Positive Experience in Clinical Trial ↗
A clinical-stage gene therapy company is making splashes in the medical world. Genprex, Inc. (NASDAQ: GNPX) is developing potentially life-changing therapies for patients with cancer and diabetes that... 
Via Benzinga
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Receives SRC Approval to Advance to Phase 2 Portion of REQORSA(R) Clinical Trial
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Results of Phase 1 Clinical Trial Will Be Published at ASCO Meeting
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces New Video Featuring Chief Medical Officer Discussing Positive Preclinical Data with NPRL2 Gene Therapy
Via Investor Brand Network
Genprex Inc. (NASDAQ: GNPX) Research Collaborators Present Positive Preclinical Data at American Association of Cancer Research 2023 Annual Meeting
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Participate and Present at Upcoming May Industry and Investor Conferences
Via Investor Brand Network
Topics Intellectual Property
News headline image
Crude Oil Up 1.5%; Philips Shares Jump After Q1 Results ↗
U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite dropping around 40 points on Monday. The Dow traded up 0.05% to 33,827.42 while the NASDAQ fell 0.33% to 12,032.16.... 
Via Benzinga
News headline image
Why IDEAYA Biosciences Shares Are Trading Higher By Around 27%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers Aclarion, Inc. (NASDAQ: ACON) shares surged 152% to $1.85 amid the publication of durability data for the company's back pain treatment. 
Via Benzinga
News headline image
US Stocks Turn Lower; Nasdaq Dips 100 Points ↗
U.S. stocks turned lower midway through trading, with the Nasdaq Composite dropping around 100 points on Monday. The Dow traded down 0.19% to 33,744.92 while the NASDAQ fell 0.84% to 11,971. The S&P... 
Via Benzinga
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Positive Data Supporting Therapeutic Potential of Its Non-Viral Delivery System
Via Investor Brand Network
News headline image
Genprex Touts Encouraging Preclinical Data From Lung Cancer Candidate ↗
Genprex Inc (NASDAQ: GNPX) announced that its research collaborators presented preclinical data for the NPRL2 gene (also known as the TUSC4 gene).  
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Sonnet BioTherapeutics Shares Are Trading Lower By Around 13%; Here Are 20 Stocks Moving Premarket ↗
Gainers Clearmind Medicine Inc. (NASDAQ: CMND) jumped 69.3% to $0.8480 in pre-market trading after dropping 12% on Tuesday. Clearmind Medicine recently announced a $3.5 million public offering priced... 
Via Benzinga
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Positive Research Findings, Additional Support for REQORSA(R) and Its Therapeutic Potential
Via Investor Brand Network
News headline image
Cancer And Diabetes Remain Among The Deadliest And Most Debilitating Diseases — Is Gene Therapy The Solution? One Company, Genprex, Inc. (NASDAQ: GNPX), Thinks So ↗
On their own, cancer or diabetes can be debilitating and deadly. The two are common diseases with tremendous impact on health worldwide. 
Via Benzinga
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Provides Statement Regarding FDA Initiative to Accelerate Approval Process for Gene Therapies
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Upcoming Barcelona Conference
Via Investor Brand Network
News headline image
Genprex’s Gene Therapy: Potential Breakthrough for Diabetes and Lung Cancer
Genprex’s Gene Therapy: Potential Breakthrough for Diabetes and Lung Cancer 
Via News Direct
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Management to Participate in Two Upcoming Conferences
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.